The benzodiazepines (BZs) are widely used drugs that are subject to abuse, and which can elicit tolerance and dependence. BZs act on neurons at specific BZ receptors which are actually modulatory sites on the receptors for GABA, the major inhibitory neurotransmitter. BZs increase GABA-mediated Cl conductance. However, all BZ/GABA receptors are not identical, and all BZs do not interact with their receptors uniformly. This variability is reflected in the tolerance that occurs during chronic treatment. For example, tolerance develops more rapidly for some measures of drug action than others, and there are differences among the BZs in degree and/or rate of tolerance development. Current work on this project has uncovered another aspect of non-uniformity of BZ tolerance. Rats that had all received the same one week flurazepam treatment were tolerant to some, but not other BZs. Thus, there may be differences among these drugs in their ability to cause tolerance, and in their ability to circumvent tolerance at the time of testing. The proposed research will seek to understand BZ tolerance at the time of testing. The proposed research will seek to understand BZ tolerance by comparing results of behavioral testing and three types of biochemical analyses. Several selected BZs will be tested after flurazepam treatments of varying lengths (to produce varying degrees of tolerance), and after treatment with certain other BZs. The patterns of tolerance and cross-tolerance may help define the requirements for a drug to allow tolerance to be displayed. Tolerance will be evaluated using several measure of anticonvulsant effects, and measures of drug-induced motor impairment. This will show if the expression of tolerance to all, or only some BZ actions is dependent on the drug used for testing. The role of the BZ/GABA receptor will be explored using two methods already shown to be useful in studies of BZ tolerance; specific binding of radio labelled BZ to receptors on neuronal membranes and a 36Cl flux assay to measure responsiveness to GABA and BZs. In addition, the expression of mRNA for the many isoforms of the GABA receptor subunits will be examined. Data from the behavioral and the three biochemical experiments will be examined, and the patterns of changes over time and among brain regions will be compared. These data should help define the role of the GABA receptor in chronic BZ actions, and may show where the changes that accompany tolerance occur in the sequence between drug-receptor interaction and the immediate physiological response (increase of GABA-stimulated Cl flux).

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA002194-15
Application #
2116517
Study Section
Drug Abuse Biomedical Research Review Committee (DABR)
Project Start
1985-02-01
Project End
1995-03-14
Budget Start
1993-09-01
Budget End
1995-03-14
Support Year
15
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Toledo
Department
Pharmacology
Type
Schools of Medicine
DUNS #
807418939
City
Toledo
State
OH
Country
United States
Zip Code
43614
Dong, Yu; Rosenberg, Howard C (2004) Brief seizure activity alters Ca2+/calmodulin dependent protein kinase II dephosphorylation and subcellular distribution in rat brain for several hours. Neurosci Lett 357:95-8
Dong, Yu; Rosenberg, Howard C (2004) Prolonged changes in Ca2+/calmodulin-dependent protein kinase II after a brief pentylenetetrazol seizure; potential role in kindling. Epilepsy Res 58:107-17
Li, M; Szabo, A; Rosenberg, H C (2001) Evaluation of native GABA(A) receptors containing an alpha 5 subunit. Eur J Pharmacol 413:63-72
Li, M; Szabo, A; Rosenberg, H C (2000) Down-regulation of benzodiazepine binding to alpha 5 subunit-containing gamma-aminobutyric Acid(A) receptors in tolerant rat brain indicates particular involvement of the hippocampal CA1 region. J Pharmacol Exp Ther 295:689-96
Walsh, L A; Li, M; Zhao, T J et al. (1999) Acute pentylenetetrazol injection reduces rat GABAA receptor mRNA levels and GABA stimulation of benzodiazepine binding with No effect on benzodiazepine binding site density. J Pharmacol Exp Ther 289:1626-33
Zhao, T J; Li, M; Chiu, T H et al. (1998) Decreased benzodiazepine binding with little effect on gamma-aminobutyric acid binding in rat brain after treatment with antisense oligodeoxynucleotide to the gamma-aminobutyric acidA receptor gamma-2 subunit. J Pharmacol Exp Ther 287:752-9
Zhao, T J; Rosenberg, H C; Chiu, T H (1996) Treatment with an antisense oligodeoxynucleotide to the GABAA receptor gamma 2 subunit increases convulsive threshold for beta-CCM, a benzodiazepine ""inverse agonist', in rats. Eur J Pharmacol 306:61-6
Tersigni, T J; Rosenberg, H C (1996) Local pressure application of cannabinoid agonists increases spontaneous activity of rat substantia nigra pars reticulata neurons without affecting response to iontophoretically-applied GABA. Brain Res 733:184-92
Rosenberg, H C (1995) Differential expression of benzodiazepine anticonvulsant cross-tolerance according to time following flurazepam or diazepam treatment. Pharmacol Biochem Behav 51:363-8
Wu, Y; Rosenberg, H C; Chiu, T H (1995) Rapid down-regulation of [3H]zolpidem binding to rat brain benzodiazepine receptors during flurazepam treatment. Eur J Pharmacol 278:125-32

Showing the most recent 10 out of 43 publications